ID   GRIA4_HUMAN             Reviewed;         902 AA.
AC   P48058; Q86XE8;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 2.
DT   27-MAR-2024, entry version 201.
DE   RecName: Full=Glutamate receptor 4;
DE            Short=GluR-4;
DE            Short=GluR4;
DE   AltName: Full=AMPA-selective glutamate receptor 4;
DE   AltName: Full=GluR-D;
DE   AltName: Full=Glutamate receptor ionotropic, AMPA 4;
DE            Short=GluA4;
DE   Flags: Precursor;
GN   Name=GRIA4 {ECO:0000303|PubMed:29220673, ECO:0000312|HGNC:HGNC:4574};
GN   Synonyms=GLUR4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8589990;
RA   Fletcher E.J., Nutt S.L., Hoo K.H., Elliott C.E., Korczak B.,
RA   McWhinnie E.A., Kamboj R.K.;
RT   "Cloning, expression and pharmacological characterization of a human
RT   glutamate receptor: hGluR4.";
RL   Recept. Channels 3:21-31(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION.
RX   PubMed=21172611; DOI=10.1016/j.neuron.2010.11.026;
RA   Kato A.S., Gill M.B., Ho M.T., Yu H., Tu Y., Siuda E.R., Wang H.,
RA   Qian Y.W., Nisenbaum E.S., Tomita S., Bredt D.S.;
RT   "Hippocampal AMPA receptor gating controlled by both TARP and cornichon
RT   proteins.";
RL   Neuron 68:1082-1096(2010).
RN   [5]
RP   INVOLVEMENT IN NEDSGA, AND VARIANTS NEDSGA SER-639; ASP-641; GLY-643;
RP   VAL-644 AND PRO-697.
RX   PubMed=29220673; DOI=10.1016/j.ajhg.2017.11.004;
RA   Martin S., Chamberlin A., Shinde D.N., Hempel M., Strom T.M., Schreiber A.,
RA   Johannsen J., Ousager L.B., Larsen M.J., Hansen L.K., Fatemi A.,
RA   Cohen J.S., Lemke J., Soerensen K.P., Helbig K.L., Lessel D.,
RA   Abou Jamra R.;
RT   "De Novo Variants in GRIA4 Lead to Intellectual Disability with or without
RT   Seizures and Gait Abnormalities.";
RL   Am. J. Hum. Genet. 101:1013-1020(2017).
CC   -!- FUNCTION: Receptor for glutamate that functions as a ligand-gated ion
CC       channel in the central nervous system and plays an important role in
CC       excitatory synaptic transmission. L-glutamate acts as an excitatory
CC       neurotransmitter at many synapses in the central nervous system.
CC       Binding of the excitatory neurotransmitter L-glutamate induces a
CC       conformation change, leading to the opening of the cation channel, and
CC       thereby converts the chemical signal to an electrical impulse. The
CC       receptor then desensitizes rapidly and enters a transient inactive
CC       state, characterized by the presence of bound agonist. In the presence
CC       of CACNG4 or CACNG7 or CACNG8, shows resensitization which is
CC       characterized by a delayed accumulation of current flux upon continued
CC       application of glutamate. {ECO:0000269|PubMed:21172611}.
CC   -!- SUBUNIT: Homotetramer or heterotetramer of pore-forming glutamate
CC       receptor subunits. Tetramers may be formed by the dimerization of
CC       dimers. Interacts with EPB41L1 via its C-terminus (By similarity).
CC       Found in a complex with GRIA1, GRIA2, GRIA3, CNIH2, CNIH3, CACNG2,
CC       CACNG3, CACNG4, CACNG5, CACNG7 and CACNG8. Interacts with CACNG5 and
CC       PRKCG (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P48058-2; Q8WTS1: ABHD5; NbExp=3; IntAct=EBI-17517256, EBI-2813554;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Postsynaptic cell membrane; Multi-pass membrane protein. Cell
CC       projection, dendrite. Note=Interaction with CNIH2, CNIH3 and PRKCG
CC       promotes cell surface expression. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P48058-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P48058-2; Sequence=VSP_042742, VSP_042743;
CC   -!- DOMAIN: The M4 transmembrane segment mediates tetramerization and is
CC       required for cell surface expression. {ECO:0000250}.
CC   -!- PTM: Palmitoylated. Depalmitoylated upon glutamate stimulation. Cys-611
CC       palmitoylation leads to Golgi retention and decreased cell surface
CC       expression. In contrast, Cys-837 palmitoylation does not affect cell
CC       surface expression but regulates stimulation-dependent endocytosis (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated at Ser-862 by PRKCG; phosphorylation increases
CC       plasma membrane-associated GRI4 expression. {ECO:0000250}.
CC   -!- DISEASE: Neurodevelopmental disorder with or without seizures and gait
CC       abnormalities (NEDSGA) [MIM:617864]: An autosomal dominant
CC       neurodevelopmental disorder characterized by global developmental delay
CC       apparent from infancy or early childhood, mild to profound intellectual
CC       disability, hypertonia early in life, which progresses to spasticity
CC       and impaired gait later, and behavioral abnormalities. Some patients
CC       may develop seizures of variable severity early in life.
CC       {ECO:0000269|PubMed:29220673}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: The postsynaptic actions of Glu are mediated by a
CC       variety of receptors that are named according to their selective
CC       agonists. This receptor binds AMPA (quisqualate) > glutamate > kainate.
CC   -!- SIMILARITY: Belongs to the glutamate-gated ion channel (TC 1.A.10.1)
CC       family. GRIA4 subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U16129; AAA95962.1; -; mRNA.
DR   EMBL; AP000641; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000673; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000813; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001561; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC045546; AAH45546.1; -; mRNA.
DR   EMBL; BC142654; AAI42655.1; -; mRNA.
DR   EMBL; BC150209; AAI50210.1; -; mRNA.
DR   CCDS; CCDS41707.1; -. [P48058-2]
DR   CCDS; CCDS8333.1; -. [P48058-1]
DR   RefSeq; NP_000820.3; NM_000829.3. [P48058-1]
DR   RefSeq; NP_001070711.2; NM_001077243.2.
DR   RefSeq; NP_001070712.1; NM_001077244.1. [P48058-2]
DR   RefSeq; NP_001106283.1; NM_001112812.1. [P48058-2]
DR   RefSeq; XP_006718886.1; XM_006718823.1. [P48058-1]
DR   AlphaFoldDB; P48058; -.
DR   SMR; P48058; -.
DR   BioGRID; 109150; 27.
DR   IntAct; P48058; 3.
DR   MINT; P48058; -.
DR   STRING; 9606.ENSP00000282499; -.
DR   BindingDB; P48058; -.
DR   ChEMBL; CHEMBL3190; -.
DR   DrugBank; DB00237; Butabarbital.
DR   DrugBank; DB05047; CX-717.
DR   DrugBank; DB00898; Ethanol.
DR   DrugBank; DB13146; Fluciclovine (18F).
DR   DrugBank; DB00142; Glutamic acid.
DR   DrugBank; DB04982; Talampanel.
DR   DrugCentral; P48058; -.
DR   GuidetoPHARMACOLOGY; 447; -.
DR   GlyCosmos; P48058; 6 sites, No reported glycans.
DR   GlyGen; P48058; 6 sites.
DR   iPTMnet; P48058; -.
DR   PhosphoSitePlus; P48058; -.
DR   BioMuta; GRIA4; -.
DR   DMDM; 218512059; -.
DR   EPD; P48058; -.
DR   jPOST; P48058; -.
DR   MassIVE; P48058; -.
DR   PaxDb; 9606-ENSP00000282499; -.
DR   PeptideAtlas; P48058; -.
DR   ProteomicsDB; 55844; -. [P48058-1]
DR   ProteomicsDB; 55845; -. [P48058-2]
DR   Antibodypedia; 31872; 524 antibodies from 37 providers.
DR   DNASU; 2893; -.
DR   Ensembl; ENST00000282499.10; ENSP00000282499.5; ENSG00000152578.15. [P48058-1]
DR   Ensembl; ENST00000393125.6; ENSP00000376833.2; ENSG00000152578.15. [P48058-2]
DR   Ensembl; ENST00000428631.6; ENSP00000415551.2; ENSG00000152578.15. [P48058-2]
DR   Ensembl; ENST00000530497.1; ENSP00000435775.1; ENSG00000152578.15. [P48058-1]
DR   GeneID; 2893; -.
DR   KEGG; hsa:2893; -.
DR   MANE-Select; ENST00000282499.10; ENSP00000282499.5; NM_000829.4; NP_000820.4.
DR   UCSC; uc001piu.2; human. [P48058-1]
DR   AGR; HGNC:4574; -.
DR   CTD; 2893; -.
DR   DisGeNET; 2893; -.
DR   GeneCards; GRIA4; -.
DR   HGNC; HGNC:4574; GRIA4.
DR   HPA; ENSG00000152578; Group enriched (brain, retina).
DR   MalaCards; GRIA4; -.
DR   MIM; 138246; gene.
DR   MIM; 617864; phenotype.
DR   neXtProt; NX_P48058; -.
DR   OpenTargets; ENSG00000152578; -.
DR   Orphanet; 528084; Non-specific syndromic intellectual disability.
DR   PharmGKB; PA28969; -.
DR   VEuPathDB; HostDB:ENSG00000152578; -.
DR   eggNOG; KOG1054; Eukaryota.
DR   GeneTree; ENSGT00940000155677; -.
DR   HOGENOM; CLU_633075_0_0_1; -.
DR   InParanoid; P48058; -.
DR   OMA; LFMERDT; -.
DR   OrthoDB; 511851at2759; -.
DR   PhylomeDB; P48058; -.
DR   TreeFam; TF315232; -.
DR   PathwayCommons; P48058; -.
DR   Reactome; R-HSA-399710; Activation of AMPA receptors.
DR   Reactome; R-HSA-399719; Trafficking of AMPA receptors.
DR   Reactome; R-HSA-416993; Trafficking of GluR2-containing AMPA receptors.
DR   Reactome; R-HSA-438066; Unblocking of NMDA receptors, glutamate binding and activation.
DR   Reactome; R-HSA-8849932; Synaptic adhesion-like molecules.
DR   SignaLink; P48058; -.
DR   SIGNOR; P48058; -.
DR   BioGRID-ORCS; 2893; 7 hits in 1150 CRISPR screens.
DR   ChiTaRS; GRIA4; human.
DR   GeneWiki; GRIA4; -.
DR   GenomeRNAi; 2893; -.
DR   Pharos; P48058; Tclin.
DR   PRO; PR:P48058; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P48058; Protein.
DR   Bgee; ENSG00000152578; Expressed in cerebellar hemisphere and 123 other cell types or tissues.
DR   ExpressionAtlas; P48058; baseline and differential.
DR   GO; GO:0032281; C:AMPA glutamate receptor complex; ISS:UniProtKB.
DR   GO; GO:0043197; C:dendritic spine; ISS:ARUK-UCL.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:1903561; C:extracellular vesicle; HDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; ISS:ARUK-UCL.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0098839; C:postsynaptic density membrane; IBA:GO_Central.
DR   GO; GO:0004971; F:AMPA glutamate receptor activity; IDA:UniProtKB.
DR   GO; GO:0001540; F:amyloid-beta binding; NAS:ARUK-UCL.
DR   GO; GO:0004970; F:glutamate-gated receptor activity; ISS:UniProtKB.
DR   GO; GO:0099507; F:ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential; IDA:SynGO.
DR   GO; GO:1904315; F:transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential; IBA:GO_Central.
DR   GO; GO:0007215; P:glutamate receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0034392; P:negative regulation of smooth muscle cell apoptotic process; IGI:ARUK-UCL.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; IBA:GO_Central.
DR   CDD; cd06388; PBP1_iGluR_AMPA_GluR4; 1.
DR   CDD; cd13727; PBP2_iGluR_AMPA_GluR4; 1.
DR   Gene3D; 1.10.287.70; -; 2.
DR   Gene3D; 3.40.50.2300; -; 2.
DR   Gene3D; 3.40.190.10; Periplasmic binding protein-like II; 2.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR019594; Glu/Gly-bd.
DR   InterPro; IPR001508; Iono_Glu_rcpt_met.
DR   InterPro; IPR015683; Ionotropic_Glu_rcpt.
DR   InterPro; IPR001320; Iontro_rcpt_C.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   InterPro; IPR001638; Solute-binding_3/MltF_N.
DR   PANTHER; PTHR18966:SF100; GLUTAMATE RECEPTOR 4; 1.
DR   PANTHER; PTHR18966; IONOTROPIC GLUTAMATE RECEPTOR; 1.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF00060; Lig_chan; 1.
DR   Pfam; PF10613; Lig_chan-Glu_bd; 1.
DR   Pfam; PF00497; SBP_bac_3; 1.
DR   PRINTS; PR00177; NMDARECEPTOR.
DR   SMART; SM00918; Lig_chan-Glu_bd; 1.
DR   SMART; SM00079; PBPe; 1.
DR   SUPFAM; SSF53822; Periplasmic binding protein-like I; 1.
DR   SUPFAM; SSF53850; Periplasmic binding protein-like II; 1.
DR   SUPFAM; SSF81324; Voltage-gated potassium channels; 1.
DR   Genevisible; P48058; HS.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Cell projection; Disease variant;
KW   Disulfide bond; Glycoprotein; Intellectual disability; Ion channel;
KW   Ion transport; Ligand-gated ion channel; Lipoprotein; Membrane; Palmitate;
KW   Phosphoprotein; Postsynaptic cell membrane; Receptor; Reference proteome;
KW   Signal; Synapse; Transmembrane; Transmembrane helix; Transport.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000255"
FT   CHAIN           21..902
FT                   /note="Glutamate receptor 4"
FT                   /id="PRO_0000011538"
FT   TOPO_DOM        22..544
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        545..565
FT                   /note="Helical"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        566..592
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   INTRAMEM        593..608
FT                   /note="Helical; Pore-forming"
FT                   /evidence="ECO:0000250"
FT   INTRAMEM        609..611
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        612..617
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        618..638
FT                   /note="Helical"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        639..813
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        814..834
FT                   /note="Helical; Name=M4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        835..902
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   BINDING         472
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000250"
FT   BINDING         500..502
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000250"
FT   BINDING         507
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000250"
FT   BINDING         676..677
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000250"
FT   BINDING         727
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         862
FT                   /note="Phosphoserine; by PKC/PRKCG"
FT                   /evidence="ECO:0000250|UniProtKB:P19493"
FT   LIPID           611
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   LIPID           837
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        52
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        56
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        258
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        371
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        407
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        414
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        84..331
FT                   /evidence="ECO:0000250"
FT   DISULFID        740..795
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         424..433
FT                   /note="ESPYVMYKKN -> PLMKNPILRN (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_042742"
FT   VAR_SEQ         434..902
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_042743"
FT   VARIANT         639
FT                   /note="T -> S (in NEDSGA; dbSNP:rs1555050158)"
FT                   /evidence="ECO:0000269|PubMed:29220673"
FT                   /id="VAR_080751"
FT   VARIANT         641
FT                   /note="N -> D (in NEDSGA; dbSNP:rs1555050165)"
FT                   /evidence="ECO:0000269|PubMed:29220673"
FT                   /id="VAR_080752"
FT   VARIANT         643
FT                   /note="A -> G (in NEDSGA; dbSNP:rs1555050171)"
FT                   /evidence="ECO:0000269|PubMed:29220673"
FT                   /id="VAR_080753"
FT   VARIANT         644
FT                   /note="A -> V (in NEDSGA; dbSNP:rs1555050174)"
FT                   /evidence="ECO:0000269|PubMed:29220673"
FT                   /id="VAR_080754"
FT   VARIANT         697
FT                   /note="R -> P (in NEDSGA; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:29220673"
FT                   /id="VAR_080755"
FT   CONFLICT        54
FT                   /note="S -> A (in Ref. 1; AAA95962)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        273
FT                   /note="I -> T (in Ref. 1; AAA95962)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        327..328
FT                   /note="NA -> KS (in Ref. 1; AAA95962)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        732..733
FT                   /note="EY -> DN (in Ref. 1; AAA95962)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   902 AA;  100871 MW;  7793AEF0AB829FC5 CRC64;
     MRIISRQIVL LFSGFWGLAM GAFPSSVQIG GLFIRNTDQE YTAFRLAIFL HNTSPNASEA
     PFNLVPHVDN IETANSFAVT NAFCSQYSRG VFAIFGLYDK RSVHTLTSFC SALHISLITP
     SFPTEGESQF VLQLRPSLRG ALLSLLDHYE WNCFVFLYDT DRGYSILQAI MEKAGQNGWH
     VSAICVENFN DVSYRQLLEE LDRRQEKKFV IDCEIERLQN ILEQIVSVGK HVKGYHYIIA
     NLGFKDISLE RFIHGGANVT GFQLVDFNTP MVIKLMDRWK KLDQREYPGS ETPPKYTSAL
     TYDGVLVMAE TFRSLRRQKI DISRRGNAGD CLANPAAPWG QGIDMERTLK QVRIQGLTGN
     VQFDHYGRRV NYTMDVFELK STGPRKVGYW NDMDKLVLIQ DVPTLGNDTA AIENRTVVVT
     TIMESPYVMY KKNHEMFEGN DKYEGYCVDL ASEIAKHIGI KYKIAIVPDG KYGARDADTK
     IWNGMVGELV YGKAEIAIAP LTITLVREEV IDFSKPFMSL GISIMIKKPQ KSKPGVFSFL
     DPLAYEIWMC IVFAYIGVSV VLFLVSRFSP YEWHTEEPED GKEGPSDQPP NEFGIFNSLW
     FSLGAFMQQG CDISPRSLSG RIVGGVWWFF TLIIISSYTA NLAAFLTVER MVSPIESAED
     LAKQTEIAYG TLDSGSTKEF FRRSKIAVYE KMWTYMRSAE PSVFTRTTAE GVARVRKSKG
     KFAFLLESTM NEYIEQRKPC DTMKVGGNLD SKGYGVATPK GSSLRTPVNL AVLKLSEAGV
     LDKLKNKWWY DKGECGPKDS GSKDKTSALS LSNVAGVFYI LVGGLGLAML VALIEFCYKS
     RAEAKRMKLT FSEAIRNKAR LSITGSVGEN GRVLTPDCPK AVHTGTAIRQ SSGLAVIASD
     LP
//